[Treatment of oropharyngeal and esophageal mycoses in immunodeficient patients with fluconazole (Diflucan, Pfizer)].
Thirteen patients with oropharyngeal and oesophageal mycosis were treated with a new triazole antimycotic, fluconazole. In the whole group in addition to the basic neoplastic disease as multifactorial predisposition to mycotic infection was revealed. After treatment a 100% clinical as well a laboratory effect was achieved. However, within one month a relapse developed in three of eight patients and reinfection in four of eight (renewal of laboratory evidence). The preparation was well tolerated by the patients, no laboratory signs of organ toxicity were revealed. In patients with cumulation of predisposing factors for mycotic infection the authors recommend long-term prophylactic protection with a small dose of fluconazole.
Háber
J
J
II. interní klinika 1. LF UK, Praha.
Kolesková
E
E
Kostelková
A
A
Klener
P
P
Slavícek
A
A
Palecek
A
A
Másová
I
I
D000328:Adult; D000368:Aged; D004935:Esophageal Diseases / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology; D009960:Oropharynx; D010608:Pharyngeal Diseases / Q000188:drug therapy* / Q000276:immunology; D010865:Pilot Projects
D015725:Fluconazole
Lécba orofaryngeální a jícnové mykózy u imunodeficitních nemocných Fluconazolem (Diflucan, Pfizer).